Diagrammed drawing of the lumbar vertebrae (lower spinal cord)

Chronic Pain Management

Move more patients from pain to relief

A large and costly problem, chronic pain affects approximately 1.5 billion people worldwide—more than heart disease, cancer and diabetes combined.1 That's why Abbott is redefining chronic pain relief.

Whether your patients experience precise or pervasive* pain, our advanced approach to neuromodulation, with two superior and proven therapies, gives you the opportunity to provide better relief.**,2,3 Our proprietary dorsal root ganglion (DRG) therapy targets certain intractable focal pain of the upper and lower extremities specific nerve damage following an injury or successful surgery,2 while our spinal cord stimulation (SCS) therapy, with revolutionary BurstDR™ stimulation,*** helps relieve pain felt broadly in the back, arms and/or legs. With Abbott, you can maximize patient outcomes by tailoring relief—because all pain is not equal.

Additionally, our radiofrequency ablation portfolio provides a minimally invasive alternative to back pain management.

Related Portfolio

Learn about an additional innovative neuromodulation therapy for patients who suffer from Parkinson’s disease, tremor or dystonia.

Deep Brain Stimulation Portfolio

Our latest DBS system enhances DBS therapy care for physicians and provides patients with a better therapy experience.

BurstDR™ Stimulation: The Naturally Superior Choice

BurstDR™ stimulation,*** exclusively from Abbott, is a proven technology—inspired by nature—that revolutionizes neurostimulation by treating the whole patient.4-6 Not only does BurstDR stimulation offer your patients superior pain relief over tonic stimulation from chronic pain that is broadly felt in the back, arms and/or legs, it also relieves the suffering associated with chronic pain.3

A majority of patients say that they prefer BurstDR stimulation when compared to traditional tonic stimulation.3

Learn more about BurstDR stimulation.

DRG Therapy: Designed to Deliver Targeted Stimulation

Now you can help patients with chronic neuropathic pain of the hand, foot, knee, hip or groin—following an injury or successful surgery—with a therapy specifically designed to relieve this type of pain.

Watch the video to see how DRG stimulation works, and learn about the Proclaim™ DRG Neurostimulation System.

Dorsal root ganglion (DRG) stimulation is a clinically proven therapy designed to deliver targeted stimulation and provide precise relief for patients with focal chronic pain conditions.2

Photograph of sun shining through green tree leaves

Transforming the Treatment of Chronic Pain

Inspired by the needs and challenges of patients with chronic pain, we believe that further innovation in the management of chronic pain will result in more effective outcomes. That is why Abbott invests in the development of objective clinical outcomes, new therapy options and patient-centric system features that we believe will lead to an improved quality of life for more patients.

Partner with us to treat more patients with better results and transform the lives of more patients suffering from chronic pain.

Contact your Abbott representative or request more information.


*Pain that is broadly felt in a large area of the body.
**When compared to traditional tonic spinal cord stimulation based on outcomes from the ACCURATE IDE study.
***BurstDR™ stimulation, patented technology exclusively from Abbott, is also referred to as Burst stimulation in clinical literature.
1. Institute of Medicine. (2011). Relieving Pain in America Report 2011. Retrieved from http://www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx.
2. Deer, TR, Levy, RM, Kramer, J, et al. (2017). Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 158(4): 669-681. http://dx.doi.org/10.1097/j.pain.0000000000000814 ACCURATE IDE STUDY, St. Jude Medical. (n=152)
3. St. Jude Medical Pre-Market Approval (PMA) Clinical Study Report for the SUNBURST™ Study: IDE #G130169 Approval date: October 3, 2016 Report number: CL1000771 version B. (n = 96).
4. American Chronic Pain Association. APCA Consumer Guide to Pain Medication and Treatment. Retrieved from http://www.theacpa.org/uploads/ACPA_Resource_Guide_2012_Update%

5. Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006). Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. European Journal of Pain, 10, 287-333. http://dx.doi.org/10.1016/j.ejpain.2005.06.009
6. European Pain Federation. (2010). Pain proposal: Improving the current and future management of chronic pain. A European consensus report. Retrieved from http://www.efic.org/index.asp?sub=B57HFCF6J4043I
7. Breivik, H., Hattori, S., & Moulin, D. E. (2005, August). Prevalence and impact of chronic pain: A systematic review of epidemiological studies on chronic pain. Presented at the meeting of the International Association for the Study of Pain (IASP) 11th World Congress on Pain, Sydney, Australia.
8. Mironer, E., Berstein, C. A., Masone, R., Garcia. E., Amayem, A., Johans, T., … Golovac, S. (2011, May). A prospective clinical evaluation of a rechargeable implantable pulse generator (IPG): Final analysis of the sustainability of spinal cord stimulation therapy for chronic lower back pain. Presented at the meeting of the International Neuromodulation Society, London, England.

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.